Breast Cancer

Controversial Avastin Spit and Ship Study to Help Triple Negative Breast Cancer Patients

Apr 16 2012 - 11:53am
Avastin and Breast Cancer

Undeterred by the U.S. Food and Drug Administration (FDA) removal of Avastin for breast cancer, makers of the drug are now seeking breast cancer patients who have previously used Avastin to provide saliva samples in a spit and ship study titled “The InVite Study” to determine if there is a subset of women with breast cancer—such as those diagnosed with triple negative breast cancer—who may still benefit from Avastin.

Latest News: 
Health and Wellness: